Elevated antigalactosyl antibody titers reflect renal injury after gold or D-penicillamine in rheumatoid arthritis.
Titers of circulating antigalactosyl antibodies (a-Gal Ab) were assessed by passive hemagglutination using rabbit red blood cells in 40 normal subjects, in 14 patients with immunodeficient states, in 47 patients with active rheumatoid arthritis (RA), and in 15 patients with an Henoch-Schönlein disease (HS). Titers of controls ranged from 1:16 to 1:64. All immunodeficient patients exhibited very low titers (1:1). On the contrary, the existence of an enhanced humoral immune response status, as observed in RA, was not reflected by a parallel increase of a-Gal Ab titers. However, in this disease, a strong relationship existed between titers exceeding control values (greater than 1:64) and the prior occurrence of renal injury under gold or D-penicillamine therapy. Lastly, the discovery of elevated titers (greater than 1:64) in HS only when renal involvement occurred further suggests that such antibodies reflect a renal injury.
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004112:Dimercaprol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006046:Gold / Q000009:adverse effects* / Q000627:therapeutic use; D006386:Hemagglutination Tests; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy / Q000276:immunology*; D007105:Immune Complex Diseases / Q000139:chemically induced* / Q000276:immunology; D007074:Immunoglobulin G / Q000032:analysis*; D007223:Infant; D007668:Kidney / Q000276:immunology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology*; D050607:Organogold Compounds; D009942:Organometallic Compounds; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D020005:Propanols; D013438:Sulfhydryl Compounds
D007074:Immunoglobulin G; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D013438:Sulfhydryl Compounds; D004112:Dimercaprol; D006046:Gold; C013394:aurotioprol; D010396:Penicillamine